Abstract
Active surveillance (AS) has been widely accepted as a first-line management approach in men with low-risk prostate cancer. While AS provides an avenue to reduce risk of overtreatment without compromising oncological safety, there remains a lack of consensus on the optimal approach to monitoring. An ideal surveillance strategy would be one that minimizes invasive testing such as prostate biopsy without conceding adverse oncologic outcomes. Thus, several studies have sought to identify men at higher risk of reclassification so as to more carefully select when biopsy is truly necessary.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
